Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland.
Kuri A, Henshall DE, Chaudhry D, Ooi SZY, Zhang Q, Mathews J, Thomson A, Rog D, Hobart J, Dobson R; Neurology and Neurosurgery Interest Group (NANSIG). Kuri A, et al. Among authors: hobart j. BMC Neurol. 2024 Mar 28;24(1):105. doi: 10.1186/s12883-024-03598-z. BMC Neurol. 2024. PMID: 38539132 Free PMC article.
The impact of smoking cessation on multiple sclerosis disease progression.
Rodgers J, Friede T, Vonberg FW, Constantinescu CS, Coles A, Chataway J, Duddy M, Emsley H, Ford H, Fisniku L, Galea I, Harrower T, Hobart J, Huseyin H, Kipps CM, Marta M, McDonnell GV, McLean B, Pearson OR, Rog D, Schmierer K, Sharrack B, Straukiene A, Wilson HC, Ford DV, Middleton RM, Nicholas R. Rodgers J, et al. Among authors: hobart j. Brain. 2022 May 24;145(4):1368-1378. doi: 10.1093/brain/awab385. Brain. 2022. PMID: 34623418 Free PMC article.
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis.
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J, Evangelou N, Scolding N, Rog D, Nicholas R, Marta M, Blain C, Young CA, Ford HL, Matthews PM. Dobson R, et al. Among authors: hobart j. BMJ Open. 2021 Nov 25;11(11):e050176. doi: 10.1136/bmjopen-2021-050176. BMJ Open. 2021. PMID: 34824113 Free PMC article.
Validating the portal population of the United Kingdom Multiple Sclerosis Register.
Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H, Griffiths D, Noble DG, Jones KH, Al-Din A, Craner M, Evangelou N, Harman P, Harrower T, Hobart J, Husseyin H, Kasti M, Kipps C, McDonnell G, Owen C, Pearson O, Rashid W, Wilson H, Ford DV. Middleton RM, et al. Among authors: hobart j. Mult Scler Relat Disord. 2018 Aug;24:3-10. doi: 10.1016/j.msard.2018.05.015. Epub 2018 May 25. Mult Scler Relat Disord. 2018. PMID: 29860199
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS).
Dobson R, Craner M, Waddingham E, Miller A, Pindoria J, Cavey A, Blain C, De Luca G, Evangelou N, Ford H, Gallagher P, George K, Geraldes Ramos Dias R, Harman P, Hobart J, King T, Linighan R, MacDougall N, Marta M, Mitchell S, Nicholas R, Rog D, Scalfari A, Scolding N, Webb S, White S, Wilton J, Young C, Matthews PM. Dobson R, et al. Among authors: hobart j. Mult Scler Relat Disord. 2022 Jul;63:103894. doi: 10.1016/j.msard.2022.103894. Epub 2022 May 20. Mult Scler Relat Disord. 2022. PMID: 35636271 Free article.
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Braisher M, Blackstone J, Ciccarelli O, Gandini Wheeler-Kingshott CAM, Barkhof F, Chataway J; UCL MS-STAT2 investigators. Williams T, et al. Eur J Neurol. 2023 Sep;30(9):2769-2780. doi: 10.1111/ene.15924. Epub 2023 Jun 23. Eur J Neurol. 2023. PMID: 37318885 Clinical Trial.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?
Chen B, Gomez-Figueroa E, Redenbaugh V, Francis A, Satukijchai C, Wu Y, Messina S, Sa M, Woodhall M, Paul F, Robertson NP, Lim M, Wassmer E, Kneen R, Huda S, Blain C, Halfpenny C, Hemingway C, O'Sullivan E, Hobart J, Fisniku LK, Martin RJ, Dobson R, Cooper SA, Williams V, Waters P, Chen JJ, Pittock SJ, Ramdas S, Leite MI, Flanagan EP, Geraldes R, Palace J. Chen B, et al. Among authors: hobart j. Ann Neurol. 2023 Sep;94(3):508-517. doi: 10.1002/ana.26731. Epub 2023 Jul 12. Ann Neurol. 2023. PMID: 37394961
182 results